This brief discussion summarizes possible trial design changes that could be utilized to reduce the number of subjects exposed to ineffective treatment--in this case placebo; however, these designs are fairly complex and have not been implemented sufficiently to judge their utility. Clearly, such studies are essential before embarking on these paradigms as a primary method for assessing antidepressant efficacy.